CN112839673A - 包含流感疫苗的组合物 - Google Patents

包含流感疫苗的组合物 Download PDF

Info

Publication number
CN112839673A
CN112839673A CN201980062008.1A CN201980062008A CN112839673A CN 112839673 A CN112839673 A CN 112839673A CN 201980062008 A CN201980062008 A CN 201980062008A CN 112839673 A CN112839673 A CN 112839673A
Authority
CN
China
Prior art keywords
vaccine
influenza
amino
composition
enhances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980062008.1A
Other languages
English (en)
Chinese (zh)
Inventor
高桥宜圣
安达悠
阿户学
福岛晃久
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Infectious Diseases
Sumitomo Pharma Co Ltd
Original Assignee
National Institute of Infectious Diseases
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute of Infectious Diseases, Sumitomo Dainippon Pharma Co Ltd filed Critical National Institute of Infectious Diseases
Publication of CN112839673A publication Critical patent/CN112839673A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980062008.1A 2018-07-23 2019-07-22 包含流感疫苗的组合物 Pending CN112839673A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2018138001 2018-07-23
JP2018-138001 2018-07-23
JP2019-038976 2019-03-04
JP2019038976 2019-03-04
PCT/JP2019/028674 WO2020022272A1 (ja) 2018-07-23 2019-07-22 インフルエンザワクチンを含む組成物

Publications (1)

Publication Number Publication Date
CN112839673A true CN112839673A (zh) 2021-05-25

Family

ID=69181520

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980062008.1A Pending CN112839673A (zh) 2018-07-23 2019-07-22 包含流感疫苗的组合物

Country Status (17)

Country Link
US (2) US12059462B2 (https=)
EP (1) EP3827842A4 (https=)
JP (1) JP7395461B2 (https=)
KR (1) KR20210034614A (https=)
CN (1) CN112839673A (https=)
AU (1) AU2019311965B2 (https=)
BR (1) BR112021001188A8 (https=)
CA (1) CA3107409A1 (https=)
IL (1) IL280332B2 (https=)
MX (1) MX2021000951A (https=)
MY (1) MY205790A (https=)
PH (1) PH12021550175A1 (https=)
SG (1) SG11202100706UA (https=)
TW (1) TW202011986A (https=)
UA (1) UA130361C2 (https=)
WO (1) WO2020022272A1 (https=)
ZA (1) ZA202101173B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
CA3121613A1 (en) * 2018-12-26 2020-07-02 Sumitomo Dainippon Pharma Co., Ltd. Preparation including vaccine adjuvant
EA202192398A1 (ru) 2019-03-04 2021-11-23 Джэпэн Эз Репризентид Баи Директор Дженерал Оф Нэшнл Инститьют Оф Инфекшес Дизизис Способ приготовления сплит-вакцины против гриппа на основе гемагглютинина
KR20220098370A (ko) * 2019-11-07 2022-07-12 세퀴러스 유케이 리미티드 감소된 입자 크기를 가지는 바이러스 백신을 제조하기 위한 조성물 및 방법
WO2021192393A1 (en) * 2020-03-27 2021-09-30 Path Malaria transmission-blocking vaccines
EP4171630A1 (en) * 2020-06-29 2023-05-03 Path Pre-erythrocytic malaria vaccines
WO2025263617A1 (ja) * 2024-06-21 2025-12-26 住友ファーマ株式会社 コレステロールとｔｌｒ７アゴニストのコンジュゲート体およびそれを含む医薬組成物
WO2026018889A1 (ja) * 2024-07-19 2026-01-22 住友ファーマ株式会社 ワクチンアジュバントを含むリポソーム製剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302317A (zh) * 2012-05-16 2015-01-21 Kj生物科学有限公司 新型和改进的流感疫苗
WO2017056494A1 (en) * 2015-09-29 2017-04-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
CN108290845A (zh) * 2015-10-07 2018-07-17 大日本住友制药株式会社 嘧啶化合物

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ES2232871T3 (es) 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Nuevos derivados de purina.
DE69817393T2 (de) 1997-11-28 2004-06-17 Sumitomo Pharmaceuticals Co., Ltd. Neue heterozyklische verbindungen
ES2221414T3 (es) 1998-08-27 2004-12-16 Sumitomo Pharmaceuticals Company, Limited Derivados de pirimidina.
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
JP2007514644A (ja) 2003-04-10 2007-06-07 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応を向上させる方法および組成物
US7799800B2 (en) 2003-08-14 2010-09-21 3M Innovative Properties Company Lipid-modified immune response modifiers
US8278083B2 (en) 2004-03-22 2012-10-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inactivated influenza virus compositions
JP4689338B2 (ja) 2005-04-26 2011-05-25 キヤノン株式会社 シート処理装置、及び画像形成装置
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
JP2009528989A (ja) 2006-02-17 2009-08-13 ファイザー・リミテッド Ｔｌｒ７変調剤としての３−デアザプリン誘導体
AR065372A1 (es) 2007-02-19 2009-06-03 Smithkline Beecham Corp Derivados de purina
ES2373616T3 (es) 2007-03-19 2012-02-07 Astrazeneca Ab Compuestos de 8-oxo-adenina 9 sustituidos como moduladores del receptor de tipo toll (tlr7).
ES2457316T3 (es) 2007-03-19 2014-04-25 Astrazeneca Ab Compuestos 8-oxo-adenina 9 sustituidos como moduladores del receptor similares a toll (TLR7)
JPWO2008114819A1 (ja) 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
HRP20120895T1 (hr) 2007-05-08 2012-11-30 Astrazeneca Ab Imidazokinolini sa imuno-modulacijskim svojstvima
CA2691444C (en) 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
FR2924024B1 (fr) 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
CA2731686C (en) 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
BRPI0917013A2 (pt) 2008-08-11 2016-02-16 Glaxosmithkline Llc métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
BRPI0917458A2 (pt) 2008-08-11 2015-12-01 Glaxosmithkline Llc composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
WO2010047509A2 (ko) 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
TR201802083T4 (tr) 2008-10-24 2018-03-21 Glaxosmithkline Biologicals Sa Lipidatlı imidazokinolin türevleri.
FR2937549B1 (fr) 2008-10-29 2011-04-01 Centre Nat Rech Scient Nanoparticules de derives beta-lactamine
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
CN101524538A (zh) 2009-03-26 2009-09-09 成都康华生物制品有限公司 一种流感-大流行流感二价联合疫苗及其制备方法
AU2010250923A1 (en) 2009-05-21 2011-11-17 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
MX2012001524A (es) 2009-08-07 2012-02-29 Glaxosmithkline Biolog Sa Derivados de oxoadenina lipidada.
EP2536425B1 (en) 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP3098236A1 (en) 2010-03-08 2016-11-30 Celltrion, Inc. Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
JP2013525431A (ja) 2010-04-30 2013-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 合成ｔｌｒ７アゴニストのリン脂質結合体の使用
US9242980B2 (en) 2010-08-17 2016-01-26 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012067268A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amide compounds and their use in the treatment of disease
WO2012067269A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
ES2627433T3 (es) 2010-12-17 2017-07-28 Sumitomo Dainippon Pharma Co., Ltd. Derivados de purina
PT3590928T (pt) 2011-04-08 2021-08-19 Janssen Sciences Ireland Unlimited Co Derivados de pirimidina para o tratamento de infeções virais
BR112013025254A2 (pt) 2011-04-21 2016-09-06 Baxter Internat Inc E Baxter Healthcare S A método para isolar um antígeno de uma composição de vacina
AU2012258220B2 (en) 2011-05-18 2017-01-19 Janssen Sciences Ireland Uc Quinazoline derivatives for the treatment of viral infections and further diseases
JP6184423B2 (ja) 2012-05-18 2017-08-23 大日本住友製薬株式会社 カルボン酸化合物
EA035431B1 (ru) 2012-11-16 2020-06-15 Янссен Сайенсиз Айрлэнд Юси Гетероциклические замещенные производные 2-амино-хиназолина в качестве модуляторов tlr7 и/или tlr8 для лечения вирусных инфекций
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
AU2015305690A1 (en) 2014-08-18 2017-03-02 Sanofi Pasteur Inc. Alkylated influenza vaccines
US11191727B2 (en) 2014-12-31 2021-12-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multivalent nanoparticle-based vaccines
EP3603619B1 (en) 2017-03-29 2025-08-13 Sumitomo Pharma Co., Ltd. Vaccine adjuvant formulation
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
CA3121613A1 (en) 2018-12-26 2020-07-02 Sumitomo Dainippon Pharma Co., Ltd. Preparation including vaccine adjuvant
EA202192398A1 (ru) 2019-03-04 2021-11-23 Джэпэн Эз Репризентид Баи Директор Дженерал Оф Нэшнл Инститьют Оф Инфекшес Дизизис Способ приготовления сплит-вакцины против гриппа на основе гемагглютинина

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302317A (zh) * 2012-05-16 2015-01-21 Kj生物科学有限公司 新型和改进的流感疫苗
WO2017056494A1 (en) * 2015-09-29 2017-04-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
CN108290845A (zh) * 2015-10-07 2018-07-17 大日本住友制药株式会社 嘧啶化合物

Also Published As

Publication number Publication date
JP7395461B2 (ja) 2023-12-11
IL280332A (en) 2021-03-25
UA130361C2 (uk) 2026-02-04
IL280332B2 (en) 2025-05-01
MY205790A (en) 2024-11-13
BR112021001188A8 (pt) 2022-12-06
SG11202100706UA (en) 2021-03-30
US20210353737A1 (en) 2021-11-18
JPWO2020022272A1 (ja) 2021-08-05
KR20210034614A (ko) 2021-03-30
PH12021550175A1 (en) 2022-07-11
WO2020022272A1 (ja) 2020-01-30
CA3107409A1 (en) 2020-01-30
EP3827842A4 (en) 2022-04-20
MX2021000951A (es) 2021-06-23
US20250009869A1 (en) 2025-01-09
TW202011986A (zh) 2020-04-01
EP3827842A1 (en) 2021-06-02
BR112021001188A2 (pt) 2021-04-27
US12059462B2 (en) 2024-08-13
AU2019311965A1 (en) 2021-02-25
IL280332B1 (en) 2025-01-01
AU2019311965B2 (en) 2026-02-19
ZA202101173B (en) 2024-08-28

Similar Documents

Publication Publication Date Title
US20250009869A1 (en) Composition containing influenza vaccine
US9545439B2 (en) Emulsion vaccine compositions comprising antigen and adjuvant in the aqueous phase
Probst et al. A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response
JP2010536878A (ja) インフルエンザタンパク質を製造および使用する組成物および方法
US20150098958A1 (en) Influenza Nucleoprotein Vaccines
US20240115693A1 (en) Sars-cov-2 antigen nanoparticles and uses there of
KR20220035870A (ko) 백신 어주번트로서의 tlr4 및 tlr7 리간드 제제
JP5735121B2 (ja) インフルエンザウィルスの組換えヘマグルチニン蛋白質及びそれを含むワクチン
CN114096273B (zh) 用于生产流感ha裂解疫苗的方法
AU2019262609A1 (en) Artificial promiscuous T helper cell epitopes that facilitate targeted antibody production with limited T cell inflammatory response
EP4370152A1 (en) Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
WO2020246584A1 (ja) ペプチド核酸を基盤としたアジュバント
EA050794B1 (ru) Композиция, входящая в состав вакцины против гриппа
HK40050918A (en) Composition containing influenza vaccine
JP2013533235A (ja) 束縛免疫原性組成物およびその用途
CN117462667B (zh) 一种复合佐剂及其在疫苗制备中的应用
Hoxie et al. A TRAC-478-adjuvanted recombinant N1 neuraminidase influenza virus vaccine induces balanced and broadly protective immune responses
EP4169513A1 (en) Adjuvant composition comprising sting agonists
TWI771546B (zh) 針對亨德拉(hendra)及尼帕(nipah)病毒感染之疫苗
WO2023240278A2 (en) Uses of glycolipids as a vaccine adjuvant and methods thereof
WO2023211281A1 (en) Antiviral vaccine composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Tokyo, Japan

Applicant after: Representative of the director of the National Institute of infectious diseases of Japan

Applicant after: SUMITOMO PHARMACEUTICALS CO.,LTD.

Address before: Tokyo, Japan

Applicant before: Representative of the director of the National Institute of infectious diseases of Japan

Applicant before: Dainippon Sumitomo Pharma Co.,Ltd.

CB02 Change of applicant information